Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 25, 2023, Danaher Corporation (NYSE: DHR) disclosed its Q1 2023 financial results. The company reported net earnings of $1.4 billion or $1.94 per diluted share, alongside non-GAAP adjusted earnings of $2.36 per share. Total revenues fell 7.0% year-over-year to $7.2 billion, attributed to reduced COVID-19 revenue, while core revenue decreased by 4.0%. However, the base business core revenue grew 6.0%. The operating cash flow for the quarter stood at $1.9 billion, with free cash flow at $1.7 billion. For Q2 and the full year, non-GAAP base business core revenue growth is projected to be in the mid-single digits. CEO Rainer M. Blair noted a strong start despite challenges, highlighting a robust business outlook.
Danaher Corporation (NYSE: DHR) announced that its 5.00% Series B Mandatory Convertible Preferred Stock will convert automatically into common stock on April 17, 2023. Shareholders will receive 5.0175 shares of common stock for each share of Preferred Stock. Additionally, a final quarterly cash dividend of $12.50 per share will be distributed to Preferred Stock holders of record as of March 31, 2023, paid on the conversion date of April 17, 2023, due to the prior dividend date falling on a weekend.
This strategic move simplifies capital structure while rewarding investors with equity and dividend payments.
Danaher Corporation (NYSE: DHR) has scheduled its first quarter 2023 earnings conference call for April 25, 2023, at 8:00 a.m. ET. The call will focus on the company's financial performance and future expectations, lasting approximately one hour.
Listeners can access the call via telephone or through a webcast on Danaher's website. The earnings press release and presentation materials will also be available on the site starting at 6:00 a.m. ET on the day of the call.
Danaher Corporation (NYSE: DHR) has announced a strategic partnership with the University of Pennsylvania to enhance cell therapy innovation. This multi-year collaboration aims to develop technologies that improve clinical outcomes and address manufacturing bottlenecks associated with engineered cell products. Currently, there are six FDA-approved CAR T cell therapies and over 560 programs in clinical trials, highlighting significant potential in the biopharma industry. Both parties believe that advancing manufacturing innovation will help deliver next-generation therapies to patients more efficiently.